Recursion
Recursion leverages advanced technology and vast datasets to build a next-generation biopharmaceutical company, conducting millions of experiments weekly and collaborating with industry leaders to accelerate drug discovery.
Services
Recursion offers a comprehensive suite of services centered around its drug discovery processes. The company conducts up to 2.2 million wet lab experiment profiling genes and compounds per week. Recursion's services are augmented by BioHive-1, one of the industry's top 500 supercomputers. With this strong technological backbone, Recursion aims to develop novel therapeutics through substantial partnerships and collaborations with companies like Bayer, Tempus, and Enamine.
Technological Infrastructure
Recursion leverages advanced technology to drive its mission of building a next-generation biopharmaceutical company. The company possesses more than 50 petabytes of proprietary data and profiles over 6 trillion gene and compound relationships. The BioHive-1 supercomputer and LLM-orchestrated Workflow Engine, LOWE, play crucial roles in orchestrating and integrating complex drug discovery workflows. Additionally, their proprietary dataset, RxRx, and tools like PhenoMap, Scaffold Shopper, and Phenom-Beta enhance their research capabilities significantly.
Collaborations
Recursion has established several strategic partnerships to advance its drug discovery initiatives. Collaborations include working with NVIDIA to accelerate AI foundation models for biology and chemistry, teaming up with Bayer to identify novel therapeutics for fibrotic diseases and precision oncology, partnering with Tempus for access to a vast oncology dataset, and collaborating with Enamine to generate enriched compound libraries. These collaborations are pivotal in extending Recursion's research and development capabilities.
Clinical Trials
Recursion is actively involved in various clinical trials for drug candidates aimed at treating rare diseases and precision oncology. Notable trials include the Phase 2 SYCAMORE trial for REC-994 targeting Cerebral Cavernous Malformation, the Phase 2/3 POPLAR trial for REC-2282 in NF2-mutated meningiomas, and the Phase 2 TUPELO trial for REC-4881 aimed at Familial Adenomatous Polyposis. Additionally, the Phase 2 proof-of-concept trial for REC-3964 to treat Clostridioides difficile infection is slated to begin in 2024.
Sustainability and Social Responsibility
Recursion is committed to sustainability and social responsibility. The company aims to achieve net-zero greenhouse gas emissions by 2030 and plans for equal gender representation, with a 50/50 split across all levels and specifically at the VP level and above by 2030. Recursion also directs 1% of its equity into the Recursion Foundation, established in 2019, to support diverse and equitable life science and technology hubs and expand STEM education for diverse youth.